JSR Life Sciences
Overview
JSR Life Sciences is a life sciences investment firm and operating company that provides integrated solutions, products, and services for drug discovery, development, and bioprocessing, while also maintaining a corporate venture arm to invest in innovative biotechnology companies.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Aqualung Therapeutics Corporation | Oct 2022 | Series A | Lead |
| Optimeos Life Sciences | Aug 2023 | Seed | Lead |
| Inhalon Biopharma Inc. | Jun 2022 | Series A | Lead |
Key People
Nalini M.
Senior Vice President of Corporate Development
Paolo Scalzini
Senior Director Corporate Development
Brad Prater
Director
Gerald Platteau
Global Director Technology and Implementation Support
Jared Young
Director, Similis Bio
Kentaro Tamaki
Director of Quality Assurance
Shinya Yamada
Director, Portfolio Management
TOMOHIRO KANEKO
Director, Strategic Planning & Global Coordination
Yuichiro Morimoto
Head of Corporate Strategy and Innovation, Chief of Staff
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is JSR Life Sciences based?
JSR Life Sciences is headquartered in Sunnyvale, California, United States.
When was JSR Life Sciences founded?
JSR Life Sciences was founded in 2012.
How many portfolio companies does JSR Life Sciences have?
JSR Life Sciences has 3 portfolio companies in Caplight's dataset.
What are some companies in JSR Life Sciences's portfolio?
Portfolio companies visible on Caplight include Aqualung Therapeutics Corporation, Optimeos Life Sciences, Inhalon Biopharma Inc..
What was JSR Life Sciences's most recent investment shown here?
JSR Life Sciences's most recent investment in this portfolio sample was in Optimeos Life Sciences in 2023.
What sectors does JSR Life Sciences focus on?
JSR Life Sciences focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences.
What company stages does JSR Life Sciences focus on?
JSR Life Sciences typically invests at the Early stage.